Evidence map›Paper›PMID 32701063›Full record

ArticleAging2020

ACE2 activator diminazene aceturate ameliorates Alzheimer's disease-like neuropathology and rescues cognitive impairment in SAMP8 mice.

Rui Duan, Xiao Xue, Qiao-Quan Zhang, Si-Yu Wang, Peng-Yu Gong, Yan E, Teng Jiang, Ying-Dong Zhang

Open access · greenAbstract read
In one paragraph

Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Microglial activation and RAS signaling: a dual-edged sword in neuroinflammation.American journal of physiology. Regulatory, integrative and comparative physiology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Knockdown ofJournal of inflammation research · 2024
    Article
  13. Article
  14. The Renin Angiotensin System as a Therapeutic Target in Traumatic Brain Injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  15. Article
  16. COVID-19 and Diarylamidines: The Parasitic Connection.International journal of molecular sciences · 2023
    Review
  17. Article
  18. Links between COVID-19 and Alzheimer's Disease-What Do We Already Know?International journal of environmental research and public health · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rui DuanSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
Xiao XueDepartment of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China.
Qiao-Quan ZhangDepartment of Pathology, Nanjing Brain Hospital, Nanjing Medical University, Nanjing 210029, People's Republic of China.
Si-Yu WangDepartment of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China.
Peng-Yu GongDepartment of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China.
Yan EDepartment of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China.
Teng JiangDepartment of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China.
Ying-Dong ZhangSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
Nanjing Medical University · CNChina Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously, we revealed that brain Ang-(1-7) deficiency was involved in the pathogenesis of sporadic Alzheimer's disease (AD). We speculated that restoration of brain Ang-(1-7) levels might have a therapeutic effect against AD. However, the relatively short duration of biological effect limited the application of Ang-(1-7) in animal experiments. Since Ang-(1-7) is generated by its metabolic enzyme ACE2, we then tested the efficacy of an ACE2 activator diminazene aceturate (DIZE) on AD-like neuropathology and cognitive impairment in senescence-accelerated mouse prone substrain 8 (SAMP8) mice, an animal model of sporadic AD. Eight-month-old SAMP8 mice were injected intraperitoneally with vehicle or DIZE once a day for 30 consecutive days. DIZE markedly elevated brain Ang-(1-7) and MAS1 levels. Meanwhile, DIZE significantly reduced the levels of Aβ

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAngiotensin-Converting Enzyme 2Angiotensin IAnimalsBrain ChemistryCognitive DysfunctionCytokinesDiminazeneInfusions, ParenteralMaleMaze LearningMiceMice, Neurologic MutantsPeptide FragmentsProto-Oncogene MasAce2 protein, mouseAmyloid beta-Peptidesamyloid beta-protein (1-42)Angiotensin-Converting Enzyme 2Angiotensin Iangiotensin I (1-7)CytokinesDiminazenediminazene aceturateMas1 protein, mousePeptide FragmentsProto-Oncogene MasProto-Oncogene ProteinsReceptors, G-Protein-Coupledtau ProteinsACE2Alzheimer’s diseaseAng-(1-7)diminazene aceturate

Identifiers

PMID32701063
PMCPMC7425432
OpenAlexW3044532039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.